®Yolia's work starts with an important idea: the optical design of treatment can be personalized to the eye. That makes myopia an interesting direction for research, because modern myopia management considers more than how clearly someone can see a distance chart today.
For children whose myopia is progressing, a central goal is to slow further progression and eye elongation over time. That is a different outcome from temporarily correcting blurred distance vision.
Optical design can influence more than clarity
Clinical trials with established optical approaches provide a scientific reason to take this field seriously. The ROMIO randomized trial evaluated orthokeratology in children using axial elongation as an outcome. The BLINK randomized trial studied soft multifocal contact lenses and found less progression with high-add lenses than with the other lens designs tested. [1,2]
These studies did not test TVT. Their relevance to Yolia is the broader lesson that optical architecture, treatment design and longitudinal measurements belong together in research on myopia.
Yolia publicly identifies myopia control as a development direction. [3] Its personalized corneal approach raises a useful question: could a deliberately designed optical profile contribute to a future myopia-management strategy?
A promising question deserves its own programme
Research in this direction would need to define the target population, map the resulting optics and follow refractive change and axial length against an appropriate comparator. Comfort, adherence, corneal health and visual quality would need to be assessed alongside any progression endpoint.
Adult presbyopia experience can inform questions about fitting and measurement. It does not establish effectiveness or safety for treating children's myopia with TVT. A multifocal corneal pattern in an adult near-vision study is also not, by itself, evidence of slowed eye growth.
That distinction gives Yolia a clear development opportunity: build a programme designed for the outcome it seeks, rather than borrowing a result from another indication or another lens.
What success could mean
If a future TVT approach safely reduced progression, the value would extend beyond a temporary improvement in unaided distance vision. A care pathway might combine personalized optics, objective growth measurements and a regimen families can follow. Each of those potential advantages would need to be demonstrated in that programme.
For now, families should discuss established myopia-management options with an eye-care professional. They should not substitute an adult presbyopia regimen for a child's prescribed treatment.
Yolia's opportunity is to bring its experience in individualized corneal design to a research question with long-term importance. The ambition is to contribute to better myopia care through evidence built specifically for that purpose.
Explore Yolia's research vision and discuss current myopia care with your clinician.
Sources
[1] Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO): a two-year randomized clinical trial. IOVS. 2012. Not a TVT study. https://pubmed.ncbi.nlm.nih.gov/22969068/
[2] Walline JJ et al. The BLINK Randomized Clinical Trial. JAMA. 2020;324:571–580. https://pmc.ncbi.nlm.nih.gov/articles/PMC7420158/
[3] Yolia Health. Development directions. https://www.yolia.com/doctors/